ERBB2 (erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) )

Identity

Other names	v-erb-b2
	HER2
	NEU
	TKR1
	NGL
	Her-2/neu
	C-erbB-2
Hugo	ERBB2
Location	17q11.2-q12

Note	tyrosine-kinase receptor (RTK). The HER family of RTKs consists of four receptors: epidermal growth factor receptor ( EGFR, also called HER-1 or erbB-1), HER-2 (also called erbB-2 or Neu), HER-3 and HER-4 (also called erbB-3 and erbB-4, respectively).

DNA/RNA

Description

Sequence length 30528; CDS 3768. 27 exons; total exon length 4477, max. exon length 969, min exon length 48. Number of SNPs 11. Polymorphisms: allelic variations at amino acid positions 654 and 655 of isoform (a) (positions 624 and 625 of isoform (b)) have been reported, with the most common Allele B1 (Ile-654/Ile-655); allele B2 (Ile-654/Val-655); allele B3 (Val-654/Val-655). This nucleotide polymorphism could be associated with development of gastric carcinoma and with breast cancer risk, particularly among younger women.

Transcription

Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. mRNA Transcript Variant : This variant (1) represents the shorter transcript but encodes the longer isoform (a) (protein: erbB-2 isoform (a)). mRNA Transcript Variant : This variant (2) (protein: erbB-2 isoform (b) contains additional exons at its 5' end and lacks an alternate 5' noncoding exon, compared to variant (1). These differences result in translation initiation at an in-frame, downstream AUG and an isoform (b) with a shorter N-terminus compared to isoform (a). mRNA Transcript Variant : herstatin HER2-ECD 1300 bp alternative erbB-2 transcript that retains intron 8. This alternative transcript specifies 340 residues identical to subdomains I and II from the extracellular domain of p185erbB-2 followed by a unique C-terminal sequence of 79 aa encoded by intron 8. The herstatin mRNA is expressed in normal human fetal kidney and liver, but is at reduced levels relative to p185erbB-2 mRNA in carcinoma cells that contain an amplified erbB-2 gene. mRNA Transcript Variant : An alternative transcript form of the human homologous gene erbB-2, containing an in-frame deletion encompassing exon 19, has been detected in human breast carcinomas.

Protein

	HER2 protein: schematic representation Receptor tyrosin-kinases (RTKs) are cell surface allosteric enzymes consisting of: an extracellular ligand-binding domain (blue) a single transmembrane (TM) domain has an extensive homology to the epidermal grow factor receptor (brown) a cytoplasmic domain with catalityc activity (green)

Description	erbB2 encodes an 185-kDa, 1255 amino acids, orphan receptor tyrosine kinase, it displays potent oncogenic activity when overexpressed. The protooncogene consists of three domains: a single transmembrane domain that separates an intracellular kinase domain from an extracellular ligand-binding domain.
Expression	HER2 protein is expressed in several human organs and tissues: normal epithelium, endometrium and ovarian epithelium and at neuromuscular level; prostate, pancreas, lung, kidney, liver, heart, hematopoietic cells. HER2 expression is low in mononuclear cells from bone marrow, peripheral blood (PB) and mobilized PB. The higher expression has been found in cord blood-derived cells. Quiescent CD34+ progenitor cells from all blood sources and resting lymphocytes are HER2 negative, but the expression of this receptor is up-regulated during cell-cycle recruitment of progenitor cells. Similarly, it increases in mature, hematopoietic proliferating cells, underlying the correlation between HER2 and the proliferating status of hematopoietic cells.
Localisation	Plasma membrane
Function	ACTIVATION AND INTERACTIONS : For the other member of the HER family, ligand binding induces receptor homo- or heterodimerization, which is essential for TKs activation and subsequent recruitment of target proteins, in turns initiating a complex signaling cascade that leads into distinct transcriptional programs. There are several HER-specific ligands. HER2, which apparently has no direct or specific ligand, plays a major coordinating role in the HER network because of its ability to enhance and stabilize the dimerization: each receptor with a specific ligand appears in fact to prefer HER-2 as its heterodimeric partner. HER-2-containing heterodimers are characterized by extremely high signaling potency because HER-2 dramatically reduces the rate of ligand dissociation, allowing strong and prolonged activation of downstream signaling pathways. SIGNALING AND CELLULAR : The most important intracellular pathways activated by HER2 are those involving mitogen activated protein kinase and phosphatidylinositol-3 kinase. HER2 expression in cancer, besides its role in proliferation, enhances and prolongs those survivals signals, associating up-regulation of this receptor to the malignant phenotype. At the same time, and depending on cellular status, the role of this receptor in controlling cell fate can also lead to differentiation and apoptosis. PHYSIOLOGICAL : Role in development and differentiation: HER2 has several non-oncogenic roles in regulating growth, differentiation, apoptosis and/or remodeling in normal mammary glands. Dominant-negative forms of HER2 have significant defects in mammary development and lactation. HER2 has an important role in development and function of heart. Cre-Lox technology to mutate erbB-2 specifically in ventricular cardiomyocytes leads to a severe cardiomyopathy. This is inferred also by the adverse cardiac side effects observed in breast cancer patients treated with the monoclonal anti-HER2 Ab Trastuzumab. HER2 has a role in control of Schwann cell myelination and it has been demonstrated that HER2 signaling is also critical for oligodendrocyte differentiation in vivo. HER2 has a dual role in both muscle spindle maintenance and survival of myoblasts. Muscle-specific HER2 KO results in fact in viable mice with a progressive defect in proprioception due to loss of muscles spindles.
Homology	Homolog to Avian erythroblastic leukemia viral (v-erb-b) oncogen 2

Mutations

Somatic

The Cancer Genome Project and Collaborative Group sequenced the erbB-2 gene from 120 primary lung tumors and identified 4% that had mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. In non small cell lung cancer (adenocarcinoma) the following erbB-2 mutations were found: insertion/duplication of GCATACGTGATG at nucleotide 2322 of the erbB-2 gene, resulting in a 4-amino acid insertion (AYVM) at codon 774. insertion of CTGTGGGCT at nucleotide 2335 of the erbB-2 gene, resulting in a 3-amino acid insertion (VGS) starting at codon 779; a 2-bp substitution in the erbB-2 gene, TT-CC at nucleotides 2263 and 2264, resulting in a leu755-to-pro (L755P) substitution; In a glioblastoma a 2740G-A transition in the erbB-2 gene that caused a glu914-to-lys substitution (E914K). In a gastric tumor a 2326G-A transition in the erbB-2 gene that caused a gly776-to-ser (G776S) substitution. In an ovarian tumor, a 2570A-G transition in the erbB-2 gene that caused an asn857-to-ser (N857S) substitution.

Implicated in

Entity	Hematological malignancies
Disease	HER2 expression can be detected in blast cells from patients with hematological malignancies including acute lymphoblastic leukemia (ALL). It could be used as a potential target for the application of HER2-directed treatment strategies in ALL including vaccination approaches.
Entity	Bladder cancer
Prognosis	HER2 is overexpressed in 25% to 40% of several human tumors and associated with the malignancy of the disease, high mitotic index and a shorter survival time for the patient. Overexpression of ErbB-2 is associated with transitional cell carcinoma of the bladder. HER2 overexpression occurs in muscle-invasive urothelial carcinomas of the bladder and is associated with worse survival; amplifications of erbB-2 gene are also frequently linked to alterations of the TOP2A gene in bladder cancer.
Entity	Breast carcinoma
Prognosis	HER-2 overexpression, occurring in 25-30% of human breast cancers, is associated to shorter time to relapse and lower overall survival. Overexpression of the erbB-2 gene, is associated with tumor aggressiveness, and with patient responsiveness to doxorubicin, cyclophosphamide, methotrexate, fluorouracil (CMF), and to paclitaxel, whereas tamoxifen was found to be ineffective and even detrimental in patients with HER2-positive tumors. In Paget's disease of breast, HER2 protein overexpression is caused by amplification of the erbB-2 gene. HER2 has a role in this disease of the breast, where the epidermis of the nipple is infiltrated by large neoplastic cells of glandular origin. It seems that binding of heregulin-alfa to the receptor complex on Paget cells results in chemotaxis of these breast cancer cells.
Entity	Cervical cancer
Prognosis	HER2 may be activated in the early stage of pathogenesis of cervical carcinoma in geriatric patients and is frequently amplified in squamous cell carcinoma of the uterine cervix.
Entity	Childhood Medulloblastoma
Prognosis	Overexpression of HER2 in medulloblastoma is associated with poor prognosis and metastasis and HER2-HER4 receptor heterodimerization is of particular biological significance in this disease.
Entity	Colorectal cancer
Prognosis	Overexpression of HER2 occurs in a significant number of colorectal cancers. It was significantly associated with poor survival and related to tumor progression in colorectal cancer.
Entity	Oral squamous cell carcinoma
Prognosis	E6/E7 proteins of HPV type 16 and HER2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Overexpression of HER2 receptor is a frequent event in oral squamous cell carcinoma and is correlated with poor survival.
Entity	Gastric cancer
Prognosis	HER2 amplification/overexpression does not seem to play a role in the molecular pathogenesis of most gastrinomas. However, mild gene amplification occurs in a subset of them, and overexpression of this receptor is associated with aggressiveness of the disease. HER2 is correlated with tumor histological differentiation and is associated with poor prognosis in well-differentiated gastric adenocarcinoma.
Entity	Germ-cell testicular tumor
Prognosis	A significant correlation was observed between HER2 overexpression and clinical outcome in germ-cell testicular tumors.
Entity	Cholangiocarcinoma
Prognosis	Increased HER2 expression contributes to the development of cholangiocarcinogenesis into an advanced stage associated with tumor metastasis. In addition, overexpression of HER2 and COX-2 correlated directly with tumor differentiation.
Entity	Lung cancer
Prognosis	HER2 is overexpressed in less than 20% of patients with non-small cell lung cancer (NSCLC) and studies have shown that overexpression of this receptor is correlated with a poor prognosis in both resected and advanced NSCLC.
Entity	Osteosarcoma
Prognosis	Higher frequency of HER2 expression has been observed in samples from patients with metastatic disease at presentation and at the time of relapse, and it correlates with worse histologic response and decreased event-free survival.
Entity	Ovarian cancer
Prognosis	Patients with HER2-overexpression have a significantly worse prognosis compared to patients with HER2-negative tumors.
Entity	Pancreatic adenocarcinoma
Prognosis	Overexpression of HER-2 in pancreatic adenocarcinoma seems to be a result of increased transcription rather than gene amplification. The coexpression of HER2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in pancreatic ductal adenocarcinoma is related to the histopathological grades and clinical stages of tumors.
Entity	Primary Fallopian tube carcinoma
Prognosis	This disease is a rare form of female cancer where the HER2 overexpression plays a role in tumorigenesis.
Entity	Prostate cancer
Prognosis	The expression of ERBB2 in prostate cancer is relatively low, but is up-modulated at onset of hormone resistance.
Entity	Salivary gland tumor
Prognosis	Several results demonstrated significant positive staining of HER2 in the salivary tumorigenic tissue but not in the surrounding non-tumorigenic tissue, pointing to a biological role in the tumorigenic process.
Entity	Synovial sarcoma
Prognosis	The presence of increased levels of HER2 in synovial sarcoma is associated with a more favorable clinical course.

To be noted

Possible therapeutic strategies: 1) growth inhibitory antibodies (like Trastuzumab), used alone or in combination with standard chemotherapeutics; 2) tyrosin kinase inhibitors (TKI); 3)active immunotherapy, because the HER2 oncoprotein is immunogenic in some breast carcinoma patients.

External links

	Nomenclature
Hugo	ERBB2
GDB	ERBB2
Entrez_Gene	ERBB2  2064  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
	Cards
Atlas	ERBB2ID162ch17q11
GeneCards	ERBB2
Ensembl	ERBB2 [Search_View]   ENSG00000141736 [Gene_View]
Genatlas	ERBB2
GeneLynx	ERBB2
eGenome	ERBB2
euGene	2064
	Genomic and cartography
GoldenPath	ERBB2  -     chr17:35109780-35138440 +  17q11.2-q12|17q21.1   [Description]    (hg18-Mar_2006)
Ensembl	ERBB2 - 17q11.2-q12|17q21.1 [CytoView]
NCBI	Mapview
OMIM	Disease map [OMIM]
HomoloGene	ERBB2
	Gene and transcription
Genbank	AB025286 [ ENTREZ ]
Genbank	AF177761 [ ENTREZ ]
Genbank	AK131568 [ ENTREZ ]
Genbank	BC080193 [ ENTREZ ]
Genbank	BC110392 [ ENTREZ ]
RefSeq	NM_001005862 [ SRS ]    NM_001005862 [ ENTREZ ]
RefSeq	NM_004448 [ SRS ]    NM_004448 [ ENTREZ ]
RefSeq	AC_000060 [ SRS ]    AC_000060 [ ENTREZ ]
RefSeq	NC_000017 [ SRS ]    NC_000017 [ ENTREZ ]
RefSeq	NT_010755 [ SRS ]    NT_010755 [ ENTREZ ]
RefSeq	NW_926828 [ SRS ]    NW_926828 [ ENTREZ ]
AceView	ERBB2 AceView - NCBI
Unigene	Hs.446352 [ SRS ]    Hs.446352 [ NCBI ]     HS446352 [ spliceNest ]
Fast-db	9595 (alternative variants)
	Protein : pattern, domain, 3D structure
SwissProt	P04626 [ SRS]    P04626 [ EXPASY ]     P04626 [ INTERPRO ]
Prosite	PS00107 PROTEIN_KINASE_ATP [ SRS ]    PS00107 PROTEIN_KINASE_ATP [ Expasy ]
Prosite	PS50011 PROTEIN_KINASE_DOM [ SRS ]    PS50011 PROTEIN_KINASE_DOM [ Expasy ]
Prosite	PS00109 PROTEIN_KINASE_TYR [ SRS ]    PS00109 PROTEIN_KINASE_TYR [ Expasy ]
Interpro	IPR000494 EGF_rcpt_L [ SRS ]    IPR000494 EGF_rcpt_L [ EBI ]
Interpro	IPR006211 Furin-like [ SRS ]    IPR006211 Furin-like [ EBI ]
Interpro	IPR006212 Furin_repeat [ SRS ]    IPR006212 Furin_repeat [ EBI ]
Interpro	IPR000719 Prot_kinase_core [ SRS ]    IPR000719 Prot_kinase_core [ EBI ]
Interpro	IPR001245 Tyr_pkinase [ SRS ]    IPR001245 Tyr_pkinase [ EBI ]
Interpro	IPR008266 Tyr_pkinase_AS [ SRS ]    IPR008266 Tyr_pkinase_AS [ EBI ]
Interpro	IPR004019 YLP_motif [ SRS ]    IPR004019 YLP_motif [ EBI ]
CluSTr	P04626
Pfam	PF00757 Furin-like [ SRS ]    PF00757 Furin-like [ Sanger ]    pfam00757 [ NCBI-CDD ]
Pfam	PF07714 Pkinase_Tyr [ SRS ]    PF07714 Pkinase_Tyr [ Sanger ]    pfam07714 [ NCBI-CDD ]
Pfam	PF01030 Recep_L_domain [ SRS ]    PF01030 Recep_L_domain [ Sanger ]    pfam01030 [ NCBI-CDD ]
Pfam	PF02757 YLP [ SRS ]    PF02757 YLP [ Sanger ]    pfam02757 [ NCBI-CDD ]
Smart	SM00261 FU [EMBL]
Smart	SM00219 TyrKc [EMBL]
Prodom	PD000001 Prot_kinase[INRA-Toulouse]
Prodom	P04626 ERBB2_HUMAN [ Domain structure ]   P04626 ERBB2_HUMAN  [ sequences sharing at least 1 domain ]
Blocks	P04626
PDB	1N8Z [ SRS ]    1N8Z [ PdbSum ],   1N8Z [ IMB ]   1N8Z [ RSDB ]
PDB	1OVC [ SRS ]    1OVC [ PdbSum ],   1OVC [ IMB ]   1OVC [ RSDB ]
PDB	1QR1 [ SRS ]    1QR1 [ PdbSum ],   1QR1 [ IMB ]   1QR1 [ RSDB ]
PDB	1S78 [ SRS ]    1S78 [ PdbSum ],   1S78 [ IMB ]   1S78 [ RSDB ]
PDB	2A91 [ SRS ]    2A91 [ PdbSum ],   2A91 [ IMB ]   2A91 [ RSDB ]
HPRD	01281
	Protein Interaction databases
DIP	P04626
IntAct	P04626
	Polymorphism : SNP, mutations, diseases
OMIM	137215;137800;164870;211980    [ map ]
GENECLINICS	137215;137800;164870;211980
SNP	ERBB2 [dbSNP-NCBI]
SNP	NM_001005862 [SNP-NCI]
SNP	NM_004448 [SNP-NCI]
SNP	ERBB2 [GeneSNPs - Utah]  ERBB2] [HGBASE - SRS]
HAPMAP	ERBB2 [HAPMAP]
COSMIC	ERBB2 [Somatic mutation (COSMIC-CGP-Sanger)]
HGMD	ERBB2
	General knowledge
Family Browser	ERBB2 [UCSC Family Browser]
SOURCE	NM_001005862
SOURCE	NM_004448
SMD	Hs.446352
SAGE	Hs.446352
Enzyme	2.7.10.1 [ Enzyme-SRS ]   2.7.10.1 [ Brenda-SRS ]   2.7.10.1 [ KEGG ]   2.7.10.1 [ WIT ]
GO	nucleotide binding [Amigo]  nucleotide binding
GO	protein-tyrosine kinase activity [Amigo]  protein-tyrosine kinase activity
GO	transmembrane receptor protein tyrosine kinase activity [Amigo]  transmembrane receptor protein tyrosine kinase activity
GO	non-membrane spanning protein tyrosine kinase activity [Amigo]  non-membrane spanning protein tyrosine kinase activity
GO	receptor signaling protein tyrosine kinase activity [Amigo]  receptor signaling protein tyrosine kinase activity
GO	receptor activity [Amigo]  receptor activity
GO	epidermal growth factor receptor activity [Amigo]  epidermal growth factor receptor activity
GO	ATP binding [Amigo]  ATP binding
GO	extracellular region [Amigo]  extracellular region
GO	cytoplasm [Amigo]  cytoplasm
GO	plasma membrane [Amigo]  plasma membrane
GO	electron transport [Amigo]  electron transport
GO	protein amino acid phosphorylation [Amigo]  protein amino acid phosphorylation
GO	protein amino acid phosphorylation [Amigo]  protein amino acid phosphorylation
GO	transmembrane receptor protein tyrosine kinase signaling pathway [Amigo]  transmembrane receptor protein tyrosine kinase signaling pathway
GO	transmembrane receptor protein tyrosine kinase signaling pathway [Amigo]  transmembrane receptor protein tyrosine kinase signaling pathway
GO	peripheral nervous system development [Amigo]  peripheral nervous system development
GO	heart development [Amigo]  heart development
GO	neuromuscular junction development [Amigo]  neuromuscular junction development
GO	motor axon guidance [Amigo]  motor axon guidance
GO	cell proliferation [Amigo]  cell proliferation
GO	electron carrier activity [Amigo]  electron carrier activity
GO	membrane [Amigo]  membrane
GO	integral to membrane [Amigo]  integral to membrane
GO	apical plasma membrane [Amigo]  apical plasma membrane
GO	transferase activity [Amigo]  transferase activity
GO	mammary gland development [Amigo]  mammary gland development
GO	negative regulation of immature T cell proliferation in the thymus [Amigo]  negative regulation of immature T cell proliferation in the thymus
GO	myelination [Amigo]  myelination
GO	identical protein binding [Amigo]  identical protein binding
GO	ErbB-3 class receptor binding [Amigo]  ErbB-3 class receptor binding
GO	positive regulation of MAP kinase activity [Amigo]  positive regulation of MAP kinase activity
GO	regulation of angiogenesis [Amigo]  regulation of angiogenesis
GO	protein heterodimerization activity [Amigo]  protein heterodimerization activity
GO	protein heterodimerization activity [Amigo]  protein heterodimerization activity
GO	phosphoinositide-mediated signaling [Amigo]  phosphoinositide-mediated signaling
GO	positive regulation of epithelial cell proliferation [Amigo]  positive regulation of epithelial cell proliferation
GO	iron-sulfur cluster binding [Amigo]  iron-sulfur cluster binding
BIOCARTA	Role of ERBB2 in Signal Transduction and Oncology    [Genes]
BIOCARTA	Trefoil Factors Initiate Mucosal Healing    [Genes]
KEGG	Calcium signaling pathway
KEGG	Dorso-ventral axis formation
KEGG	Focal adhesion
KEGG	Adherens junction
PubGene	ERBB2
TreeFam	ERBB2
CTD	2064 [Comparative ToxicoGenomics Database]
	Other databases
	Probes
Probe	ERBB2 Related clones (RZPD - Berlin)
	PubMed
PubMed	473 Pubmed reference(s) in LocusLink

Bibliography

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL

Science (New York, N.Y.). 1987 ; 235 (4785) : 177-182.

PMID 3798106

EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling.

Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH

Science (New York, N.Y.). 1990 ; 248 (4951) : 79-83.

PMID 2181668

G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene.

Papewalis J, Nikitin AYu, Rajewsky MF

Nucleic acids research. 1991 ; 19 (19) : page 5452.

PMID 1681519

Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma.

Tateishi M, Toda T, Minamisono Y, Nagasaki S

Journal of surgical oncology. 1992 ; 49 (4) : 209-212.

PMID 1348293

Long-term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis.

Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T, Tsuneyoshi M

Cancer. 1994 ; 74 (11) : 2896-2907.

PMID 7954254

ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix.

Mitra AB, Murty VV, Pratap M, Sodhani P, Chaganti RS

Cancer research. 1994 ; 54 (3) : 637-639.

PMID 7905784

erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection.

Motojima K, Furui J, Kohara N, Izawa K, Kanematsu T, Shiku H

Surgery. 1994 ; 115 (3) : 349-354.

PMID 7907434

Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE

Molecular and cellular biology. 1995 ; 15 (12) : 6496-6505.

PMID 8524214

The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia.

Bˆºhring HJ, Sures I, Jallal B, Weiss FU, Busch FW, Ludwig WD, Handgretinger R, Waller HD, Ullrich A

Blood. 1995 ; 86 (5) : 1916-1923.

PMID 7544646

Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.

Gilbertson RJ, Pearson AD, Perry RH, Jaros E, Kelly PJ

British journal of cancer. 1995 ; 71 (3) : 473-477.

PMID 7880726

Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3.

Horan T, Wen J, Arakawa T, Liu N, Brankow D, Hu S, Ratzkin B, Philo JS

The Journal of biological chemistry. 1995 ; 270 (41) : 24604-24608.

PMID 7592681

Requirement for neuregulin receptor erbB2 in neural and cardiac development.

Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C

Nature. 1995 ; 378 (6555) : 394-398.

PMID 7477377

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 ; 14 (10) : 2702-2708.

PMID 8874330

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.

Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y

Molecular and cellular biology. 1996 ; 16 (10) : 5276-5287.

PMID 8816440

Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.

Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J

Cancer research. 1997 ; 57 (15) : 3272-3280.

PMID 9242460

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Graus-Porta D, Beerli RR, Daly JM, Hynes NE

The EMBO journal. 1997 ; 16 (7) : 1647-1655.

PMID 9130710

Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma.

Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, Clayman GL, Katz RL, Hung MC

Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 ; 3 (1) : 3-9.

PMID 9815530

Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.

Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Mˆ©nard S

Oncogene. 1998 ; 17 (4) : 425-432.

PMID 9696035

A novel splice variant of HER2 with increased transformation activity.

Kwong KY, Hung MC

Molecular carcinogenesis. 1998 ; 23 (2) : 62-68.

PMID 9808159

ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE

Molecular and cellular biology. 1998 ; 18 (9) : 5042-5051.

PMID 9710588

Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle.

Balsari A, Casalini P, Tagliabue E, Greco M, Pilotti S, Agresti R, Giovanazzi R, Alasio L, Rumio C, Cascinelli N, Colnaghi MI, Mˆ©nard S

The American journal of pathology. 1999 ; 155 (5) : 1543-1547.

PMID 10550311

The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor.

Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM

Proceedings of the National Academy of Sciences of the United States of America. 1999 ; 96 (19) : 10869-10874.

PMID 10485918

Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors.

Mˆ©nard S, Casalini P, Tomasic G, Pilotti S, Cascinelli N, Bufalino R, Perrone F, Longhi C, Rilke F, Colnaghi MI

Breast cancer research and treatment. 1999 ; 55 (2) : 169-177.

PMID 10481944

Identification of a novel promoter and exons of the c-ERBB-2 gene.

Nezu M, Sasaki H, Kuwahara Y, Ochiya T, Yamada Y, Sakamoto H, Tashiro H, Yamazaki M, Ikeuchi T, Saito Y, Terada M

Biochemical and biophysical research communications. 1999 ; 258 (3) : 499-505.

PMID 10329415

Primary cancer of the fallopian tube with transitional differentiation. Clinical and pathological assessment of 6 cases.

Rabczy‰Ñski JK, Kochman AT

Neoplasma. 1999 ; 46 (2) : 128-131.

PMID 10466438

Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma.

Chung TK, Cheung TH, To KF, Wong YF

Gynecologic and obstetric investigation. 2000 ; 49 (1) : 47-51.

PMID 10629373

A dual role of erbB2 in myelination and in expansion of the schwann cell precursor pool.

Garratt AN, Voiculescu O, Topilko P, Charnay P, Birchmeier C

The Journal of cell biology. 2000 ; 148 (5) : 1035-1046.

PMID 10704452

The ErbB signaling network: receptor heterodimerization in development and cancer.

Olayioye MA, Neve RM, Lane HA, Hynes NE

The EMBO journal. 2000 ; 19 (13) : 3159-3167.

PMID 10880430

Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family.

Schelfhout VR, Coene ED, Delaey B, Thys S, Page DL, De Potter CR

Journal of the National Cancer Institute. 2000 ; 92 (8) : 622-628.

PMID 10772679

Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W

Journal of the National Cancer Institute. 2000 ; 92 (5) : 412-417.

PMID 10699071

Role of p53 in HER2-induced proliferation or apoptosis.

Casalini P, Botta L, Menard S

The Journal of biological chemistry. 2001 ; 276 (15) : 12449-12453.

PMID 11278558

HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.

Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondˆ„n G, Champlin RE, Sahin AA, Ueno NT

Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 ; 7 (12) : 4008-4012.

PMID 11751494

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

Mˆ©nard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 ; 19 (2) : 329-335.

PMID 11208823

Untangling the ErbB signalling network.

Yarden Y, Sliwkowski MX

Nature reviews. Molecular cell biology. 2001 ; 2 (2) : 127-137.

PMID 11252954

c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.

Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M

Histopathology. 2002 ; 40 (3) : 269-278.

PMID 11895493

ErbB2 is required for muscle spindle and myoblast cell survival.

Andrechek ER, Hardy WR, Girgis-Gabardo AA, Perry RL, Butler R, Graham FL, Kahn RC, Rudnicki MA, Muller WJ

Molecular and cellular biology. 2002 ; 22 (13) : 4714-4722.

PMID 12052879

ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.

Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE

Hepatology (Baltimore, Md.). 2002 ; 36 (2) : 439-450.

PMID 12143054

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R

Cancer. 2002 ; 95 (5) : 1009-1015.

PMID 12209684

Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.

Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, Jensen RT

Cancer research. 2002 ; 62 (13) : 3702-3710.

PMID 12097278

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.

Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA Jr

British journal of cancer. 2002 ; 86 (9) : 1449-1456.

PMID 11986780

[Expression and clinical significance of p53 and c-erbB2 in geriatric women with cervical carcinoma]

Huang YW, Li MD, Wu QL, Liu FY

Ai zheng = Aizheng = Chinese journal of cancer. 2002 ; 21 (3) : 297-300.

PMID 12451999

Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.

Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D, Haffty BG

Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 ; 8 (2) : 540-548.

PMID 11839675

Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas.

Knˆ�sel T, Yu Y, Stein U, Schwabe H, Schlˆºns K, Schlag PM, Dietel M, Petersen I

Clinical & experimental metastasis. 2002 ; 19 (5) : 401-407.

PMID 12198768

HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.

Mˆ©nard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N

Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 ; 8 (2) : 520-525.

PMID 11839672

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.

Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hˆºbner N, Chien KR, Birchmeier C, Garratt AN

Proceedings of the National Academy of Sciences of the United States of America. 2002 ; 99 (13) : 8880-8885.

PMID 12072561

Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.

Savinainen KJ, Saramˆ§ki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, Visakorpi T

The American journal of pathology. 2002 ; 160 (1) : 339-345.

PMID 11786427

Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma.

Zhang L, Yuan SZ

Hepatobiliary & pancreatic diseases international : HBPD INT. 2002 ; 1 (4) : 620-623.

PMID 14607699

Immunohistological study of NM 23 and C-erbB-2 expression in primary tumor and metastases of colorectal adenocarcinoma.

Delektorskaya VV, Perevoshchikov AG, Kushlinskii NE

Bulletin of experimental biology and medicine. 2003 ; 135 (5) : 489-494.

PMID 12910292

Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.

Junttila TT, Laato M, Vahlberg T, Sˆ�derstrˆ�m KO, Visakorpi T, Isola J, Elenius K

Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 ; 9 (14) : 5346-5357.

PMID 14614020

The role of ErbB2 signaling in the onset of terminal differentiation of oligodendrocytes in vivo.

Kim JY, Sun Q, Oglesbee M, Yoon SO

The Journal of neuroscience : the official journal of the Society for Neuroscience. 2003 ; 23 (13) : 5561-5571.

PMID 12843257

A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer.

Kuraoka K, Matsumura S, Hamai Y, Nakachi K, Imai K, Matsusaki K, Oue N, Ito R, Nakayama H, Yasui W

International journal of cancer. Journal international du cancer. 2003 ; 107 (4) : 593-596.

PMID 14520697

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder.

Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA, Bartlett JM

British journal of cancer. 2003 ; 89 (7) : 1305-1309.

PMID 14520464

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

Moliterni A, Mˆ©nard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S, Bonadonna G

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 ; 21 (3) : 458-462.

PMID 12560435

Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches.

Mˆºller MR, Grˆºnebach F, Kayser K, Vogel W, Nencioni A, Brugger W, Kanz L, Brossart P

Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 ; 9 (9) : 3448-3453.

PMID 12960136

Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies.

Nagler RM, Kerner H, Ben-Eliezer S, Minkov I, Ben-Itzhak O

Oncology. 2003 ; 64 (4) : 389-398.

PMID 12759537

Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.

Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N, Kato H

International journal of cancer. Journal international du cancer. 2003 ; 103 (1) : 61-66.

PMID 12455054

Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma.

Nuciforo PG, Pellegrini C, Fasani R, Maggioni M, Coggi G, Parafioriti A, Bosari S

Human pathology. 2003 ; 34 (7) : 639-645.

PMID 12874758

HER-2 and TOP2A coamplification in urinary bladder cancer.

Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G

International journal of cancer. Journal international du cancer. 2003 ; 107 (5) : 764-772.

PMID 14566826

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G

Diagnostic molecular pathology : the American journal of surgical pathology, part B. 2003 ; 12 (4) : 201-211.

PMID 14639106

Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification.

Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE

Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology. 2003 ; 25 (1) : 27-32.

PMID 12544770

E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells.

Al Moustafa AE, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron J, Batist G, Alpert L, Alaoui-Jamali MA

Oncogene. 2004 ; 23 (2) : 350-358.

PMID 14724563

Solution structure of ADO1, a toxin extracted from the saliva of the assassin bug, Agriosphodrus dohrni.

Bernard C, Corzo G, Adachi-Akahane S, Foures G, Kanemaru K, Furukawa Y, Nakajima T, Darbon H

Proteins. 2004 ; 54 (2) : 195-205.

PMID 14696181

HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group.

Camilleri-Broˆ´t S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J, GINECO group, Pujade-Lauraine E

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004 ; 15 (1) : 104-112.

PMID 14679128

Role of HER receptors family in development and differentiation.

Casalini P, Iorio MV, Galmozzi E, Mˆ©nard S

Journal of cellular physiology. 2004 ; 200 (3) : 343-350.

PMID 15254961

beta-Catenin and p53 analyses of a breast carcinoma tissue microarray.

Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL

Cancer. 2004 ; 100 (10) : 2084-2092.

PMID 15139049

Genetic and pathologic significance of 1p, 17p, and 18q aneusomy and the ERBB2 gene in colorectal cancer and related normal colonic mucosa.

Cianciulli A, Cosimelli M, Marzano R, Merola R, Piperno G, Sperduti I, de la Iglesia F, Leonardo G, Graziano F, Mancini R, Guadagni F

Cancer genetics and cytogenetics. 2004 ; 151 (1) : 52-59.

PMID 15120910

The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters.

Essapen S, Thomas H, Green M, De Vries C, Cook MG, Marks C, Topham C, Modjtahedi H

International journal of oncology. 2004 ; 24 (2) : 241-248.

PMID 14719098

Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).

Hermanovˆ° M, Lukˆ°s Z, Nenutil R, Brˆ°zdil J, Kroupovˆ° I, Kren L, Pazourkovˆ° M, R‰Øzicka M, Dˆ‚te P

Neoplasma. 2004 ; 51 (2) : 77-83.

PMID 15190415

The role of HER2/neu expression and trastuzumab in non-small cell lung cancer.

Hirsch FR, Langer CJ

Seminars in oncology. 2004 ; 31 (1 Suppl 1) : 75-82.

PMID 14981584

Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.

Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT

Cancer research. 2004 ; 64 (6) : 2047-2053.

PMID 15026342

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.

Konecny GE, Thomssen C, Lˆºck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mˆ�bus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jˆ§nicke F, Slamon DJ

Journal of the National Cancer Institute. 2004 ; 96 (15) : 1141-1151.

PMID 15292386

ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.

Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J, Butzow R

Gynecologic oncology. 2004 ; 92 (1) : 31-39.

PMID 14751135

Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.

Mˆ°ndoky L, Gˆ©czi L, Bodrogi I, Tˆ„th J, Csuka O, Kˆ°sler M, Bak M

Anticancer research. 2004 ; 24 (4) : 2219-2224.

PMID 15330164

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.

Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS

Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 ; 10 (1 Pt 1) : 136-143.

PMID 14734462

The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.

Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J

Gynecologic oncology. 2004 ; 95 (1) : 89-94.

PMID 15385115

Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR

Nature. 2004 ; 431 (7008) : 525-526.

PMID 15457249

REVIEW articles	automatic search in PubMed
Last year publications	automatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written	12-2004	Patrizia Casalini, Marilena V Iorio
		Molecular Targeting Unit, Experimental Oncology Dept., Istituto Nazionale Tumori, Via Venezian, 1. 20133 Milano, Italy

Citation

This paper should be referenced as such :

Casalini P, Iorio MV . ERBB2 (erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) ). Atlas Genet Cytogenet Oncol Haematol. December 2004 . URL : http://AtlasGeneticsOncology.org/Genes/ERBB2ID162ch17q11.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Wed Jul 2 08:23:21 2008